EMERGENT BIOSOLUTIONS INC. Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest
EMERGENT BIOSOLUTIONS INC. (EBS) reported Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest of -$25.00 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-08.
Discontinued › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest · last filed 2019-05-08
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2019-03-31 was -$25.00M.
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-12-31 was -$4.31M, a 112.67% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-09-30 was $20.70M, a 37.77% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for the quarter ending 2018-06-30 was $51.31M, a 959.23% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2018 was $60.90M, a 26.80% decline from fiscal 2017.
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2017 was $83.20M, a 65.74% increase from fiscal 2016.
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2016 was $50.20M, a 20.53% decline from fiscal 2015.
- EMERGENT BIOSOLUTIONS INC. comprehensive income (loss), net of tax, including portion attributable to noncontrolling interest for fiscal 2015 was $63.16M, a 69.81% increase from fiscal 2014.
| Period end | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month as first filed | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month | Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month as first filed |
|---|---|---|---|---|---|---|
| 2019-03-31 | -$25.00M 10-Q · filed 2019-05-08 | -$29.31M derived: sum of 2 quarters · filed 2019-05-08 | -$8.62M derived: sum of 3 quarters · filed 2019-05-08 | $42.69M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2018-12-31 | -$4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $16.38M derived: sum of 2 quarters · filed 2019-02-22 | $67.69M derived: sum of 3 quarters · filed 2019-02-22 | $60.90M 10-K · filed 2019-02-22 | ||
| 2018-09-30 | $20.70M 10-Q · filed 2018-11-02 | $72.00M derived: sum of 2 quarters · filed 2018-11-02 | $65.21M 10-Q · filed 2018-11-02 | $101.54M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2018-06-30 | $51.31M 10-Q · filed 2018-08-03 | $44.52M 10-Q · filed 2018-08-03 | $80.84M derived: sum of 3 quarters · filed 2019-05-08 | $114.10M derived: sum of 4 quarters · filed 2019-05-08 | ||
| 2018-03-31 | -$4.50M 10-Q · filed 2019-05-08 | -$4.46M 10-Q · filed 2018-05-04 | $29.53M derived: sum of 2 quarters · filed 2019-05-08 | $62.79M derived: sum of 3 quarters · filed 2019-05-08 | $67.63M derived: sum of 4 quarters · filed 2019-05-08 | |
| 2017-12-31 | $34.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $67.29M derived: sum of 2 quarters · filed 2019-02-22 | $72.13M derived: sum of 3 quarters · filed 2019-02-22 | $83.20M 10-K · filed 2019-02-22 | $83.23M 10-K · filed 2018-02-23 | |
| 2017-09-30 | $33.26M 10-Q · filed 2018-11-02 | $38.10M derived: sum of 2 quarters · filed 2018-11-02 | $49.17M 10-Q · filed 2018-11-02 | $85.84M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-06-30 | $4.84M 10-Q · filed 2018-08-03 | $15.91M 10-Q · filed 2018-08-03 | $52.59M derived: sum of 3 quarters · filed 2019-02-22 | $73.44M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2017-03-31 | $11.07M 10-Q · filed 2018-05-04 | $47.74M derived: sum of 2 quarters · filed 2019-02-22 | $68.59M derived: sum of 3 quarters · filed 2019-02-22 | $58.72M derived: sum of 4 quarters · filed 2019-02-22 | ||
| 2016-12-31 | $36.67M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $57.52M derived: sum of 2 quarters · filed 2019-02-22 | $47.65M derived: sum of 3 quarters · filed 2019-02-22 | $50.20M 10-K · filed 2019-02-22 | $50.16M 10-K · filed 2017-02-28 | |
| 2016-09-30 | $20.85M 10-Q · filed 2017-11-03 | $10.97M derived: sum of 2 quarters · filed 2017-11-03 | $13.53M 10-Q · filed 2017-11-03 | $48.31M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-06-30 | -$9.88M 10-Q · filed 2017-08-04 | -$7.32M 10-Q · filed 2017-08-04 | $27.46M derived: sum of 3 quarters · filed 2018-02-23 | $63.91M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2016-03-31 | $2.55M 10-Q · filed 2017-05-05 | $37.34M derived: sum of 2 quarters · filed 2018-02-23 | $73.79M derived: sum of 3 quarters · filed 2018-02-23 | $87.47M derived: sum of 4 quarters · filed 2018-02-23 | ||
| 2015-12-31 | $34.79M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $71.23M derived: sum of 2 quarters · filed 2018-02-23 | $84.92M derived: sum of 3 quarters · filed 2018-02-23 | $63.16M 10-K · filed 2018-02-23 | ||
| 2015-09-30 | $36.45M 10-Q · filed 2016-11-09 | $36.45M 10-Q · filed 2015-11-06 | $50.13M derived: sum of 2 quarters · filed 2016-11-09 | $28.38M 10-Q · filed 2016-11-09 | $59.30M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | $13.69M 10-Q · filed 2016-08-05 | -$8.07M 10-Q · filed 2016-08-05 | $22.85M derived: sum of 3 quarters · filed 2017-02-28 | $44.12M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2015-03-31 | -$21.75M 10-Q · filed 2016-05-06 | $9.16M derived: sum of 2 quarters · filed 2017-02-28 | $30.44M derived: sum of 3 quarters · filed 2017-02-28 | $35.60M derived: sum of 4 quarters · filed 2017-02-28 | ||
| 2014-12-31 | $30.92M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $52.19M derived: sum of 2 quarters · filed 2017-02-28 | $57.36M derived: sum of 3 quarters · filed 2017-02-28 | $37.20M 10-K · filed 2017-02-28 | ||
| 2014-09-30 | $21.27M 10-Q · filed 2015-11-06 | $26.44M derived: sum of 2 quarters · filed 2015-11-06 | $6.28M 10-Q · filed 2015-11-06 | $21.54M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-06-30 | $5.17M 10-Q · filed 2015-08-06 | -$14.99M 10-Q · filed 2015-08-06 | $265.00K derived: sum of 3 quarters · filed 2016-02-29 | $13.77M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2014-03-31 | -$20.16M 10-Q · filed 2015-05-08 | -$4.90M derived: sum of 2 quarters · filed 2016-02-29 | $8.60M derived: sum of 3 quarters · filed 2016-02-29 | $19.33M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | $15.26M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $28.76M derived: sum of 2 quarters · filed 2016-02-29 | $39.49M derived: sum of 3 quarters · filed 2016-02-29 | $31.80M 10-K · filed 2016-02-29 | ||
| 2013-09-30 | $13.50M 10-Q · filed 2014-11-10 | $24.23M derived: sum of 2 quarters · filed 2014-11-10 | $16.54M 10-Q · filed 2014-11-10 | $32.42M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2013-06-30 | $10.73M 10-Q · filed 2014-08-08 | $3.04M 10-Q · filed 2014-08-08 | $18.92M derived: sum of 3 quarters · filed 2015-03-09 | $24.88M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2013-03-31 | -$7.69M 10-Q · filed 2014-05-12 | $8.19M derived: sum of 2 quarters · filed 2015-03-09 | $14.15M derived: sum of 3 quarters · filed 2015-03-09 | $21.76M derived: sum of 4 quarters · filed 2015-03-09 | ||
| 2012-12-31 | $15.88M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-09 | $21.84M derived: sum of 2 quarters · filed 2015-03-09 | $29.46M derived: sum of 3 quarters · filed 2015-03-09 | $22.71M 10-K · filed 2015-03-09 | ||
| 2012-09-30 | $5.96M 10-Q · filed 2013-11-08 | $13.58M derived: sum of 2 quarters · filed 2013-11-08 | $6.83M 10-Q · filed 2013-11-08 | $35.07M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-06-30 | $7.61M 10-Q · filed 2013-08-06 | $864.00K 10-Q · filed 2013-08-06 | $29.11M derived: sum of 3 quarters · filed 2014-03-10 | $30.53M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2012-03-31 | -$6.75M 10-Q · filed 2013-05-03 | $21.49M derived: sum of 2 quarters · filed 2014-03-10 | $22.92M derived: sum of 3 quarters · filed 2014-03-10 | $37.16M derived: sum of 4 quarters · filed 2014-03-10 | ||
| 2011-12-31 | $28.24M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-10 | $29.66M derived: sum of 2 quarters · filed 2014-03-10 | $43.91M derived: sum of 3 quarters · filed 2014-03-10 | $21.82M 10-K · filed 2014-03-10 | ||
| 2011-09-30 | $1.43M 10-Q · filed 2012-11-01 | $15.67M derived: sum of 2 quarters · filed 2012-11-01 | -$6.42M 10-Q · filed 2012-11-01 | |||
| 2011-06-30 | $14.24M 10-Q · filed 2012-08-03 | -$7.85M 10-Q · filed 2012-08-03 | ||||
| 2011-03-31 | -$22.09M 10-Q · filed 2012-05-04 | |||||
| 2010-12-31 | $51.06M 10-K · filed 2013-03-08 | |||||
| 2009-12-31 | $30.53M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |